Australian company Starpharma (ASX:SPL) has signed a new research partnership with Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical to develop several DEP nanoparticle formulations for an anti-infective drug.
The company said the agreement also provides for the potential to conduct additional DEP programs that can be across therapeutic areas beyond anti-infectives.
Under the partnership, Starpharma will initially develop DEP nanoparticle formulations for an anti-infective product for Chase Sun with the view of enhancing its performance and expanding its therapeutic utility.
Chase Sun will fund all activities under the agreement and all costs associated with the further development of any DEP product. In the event that Chase Sun wishes to commercialise any of the resultant DEP products, a licence agreement will be entered into with Starpharma.
Dr Jackie Fairley, Starpharma CEO, said, “We are delighted to sign this new DEP partnership with Chase Sun. Chase Sun are a rapidly growing and innovative company in an important global market. This agreement illustrates the broad applicability of the DEP platform and will further develop the commercial potential of DEP in the anti-infective space, a therapeutic area of growing interest and need."